Celebrex Should Stay On Market, FDA Panel Says, But Splits On Vioxx, Bextra

Pfizer's COX-2 inhibitor Celebrex can remain on the market with new labeling warnings, including a "black box" about the increased risk of cardiovascular events, an FDA advisory committee recommended Feb. 18